Health & Fitness
Fri, October 29, 2010Thu, October 28, 2010Wed, October 27, 2010Tue, October 26, 2010Mon, October 25, 2010Sun, October 24, 2010Sat, October 23, 2010Fri, October 22, 2010Thu, October 21, 2010Wed, October 20, 2010Tue, October 19, 2010Mon, October 18, 2010Sun, October 17, 2010Sat, October 16, 2010Fri, October 15, 2010Thu, October 14, 2010Wed, October 13, 2010Tue, October 12, 2010Mon, October 11, 2010AVEO Pharmaceuticals, Inc. Announces Timing for Third Quarter 2010 Financial Results, Webcast and Conference Call
Published in Health and Fitness on Thursday, October 21st 2010 at 3:40 GMT by Market Wire
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the companya™s third quarter ended September 30, 2010 will be released before the market opens on Thursday, November 4, 2010. The AVEO management team will host a conference call discussing the companya™s financial results, recent developments and 2010 guidance on Thursday, November 4, 2010 at 10:00 a.m. (EDT). The call can be accessed by dialing 1-866-713-8563 (domestic) or 1-617-597-5311 (international) five minutes prior to the start of the call and providing the passcode 21275874. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 75499695. The replay will be available for two weeks from the date of the live call.
The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the AVEO website at [ http://investor.aveopharma.com ]. A replay of the webcast will be archived on the companya™s website for two weeks following the call.
About AVEO
AVEO Pharmaceuticals (NASDAQ: AVEO) integrates a proprietary cancer biology platform with drug development and commercial expertise in its efforts to discover and develop targeted cancer therapeutics. The companya™s lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with a highly differentiated profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEOa™s proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development and has provided a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets includingHGF, ErbB3, RON, Notch andFGFR. For more information, please visit the company's website at [ www.aveopharma.com ].
